Causeway Capital Management LLC Buys 191,465 Shares of Pfizer Inc. $PFE

Key Points

• Causeway Capital Management LLC has increased its stake in Pfizer Inc. by 10.4%, now holding over 2 million shares, which are valued at approximately $51.3 million.
• Pfizer recently posted quarterly earnings of $0.78 EPS, exceeding expectations and achieving a revenue of $14.65 billion, up 10.3% year-over-year.
• Despite these positive earnings, Pfizer's stock is currently down by 2.8%, with a market cap of $142.99 billion and an average target price among analysts set at $28.12.

Causeway Capital Management LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,024,255 shares of the biopharmaceutical company's stock after buying an additional 191,465 shares during the quarter. Pfizer comprises about 1.1% of Causeway Capital Management LLC's investment portfolio, making the stock its 23rd biggest holding. Causeway Capital Management LLC's holdings in Pfizer were worth $51,295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. purchased a new position in shares of Pfizer in the first quarter worth $28,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter worth $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock traded up $0.16 during mid-day trading on Wednesday, reaching $25.08. 31,814,192 shares of the stock traded hands, compared to its average volume of 44,824,848. The stock has a market capitalization of $142.57 billion, a PE ratio of 13.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The business's 50-day moving average is $24.76 and its 200-day moving average is $24.40.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Leerink Partners decreased their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Berenberg Bank decreased their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Morgan Stanley boosted their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Finally, The Goldman Sachs Group boosted their price target on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.